Novo Nordisk Insider Offloads DKK 3.4 Million in Shares as Bernstein Lifts Target but Keeps Sell Rating
Published on 11/09/2026 at 06:51 | Editorial boerse-global.de
Novo Nordisk's head of research and development has trimmed his stake in the Danish drugmaker. Martin Holst Lange, who serves as Executive Vice President and scientific chief, sold 12,000 B-shares at DKK 285.00 apiece on Wednesday, a transaction executed on Nasdaq Copenhagen and disclosed the following day. The disposal was worth DKK 3,420,000.00 in total.
The insider sale landed in a busy week for the company, which also bought back 1.44 million of its own B-shares on Tuesday, spending roughly DKK 377 million under its existing repurchase programme.
Bernstein Raises Target, Sticks to Bearish Call
On Friday, Bernstein Research lifted its price target on Novo Nordisk from DKK 203 to DKK 223, according to media reports. The upgrade to the target did not come with a friendlier view of the stock: the brokerage reaffirmed its "Underperform" rating, keeping a sell recommendation in place. A higher target, in other words, does not signal a more bullish stance from the analysts.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Guidance Raised on Strong Third-Quarter Operating Profit
The backdrop to the week's developments is Novo Nordisk's upgraded full-year outlook, announced on Wednesday. The company now expects adjusted revenue growth of between minus 2% and plus 2% for 2026, measured at constant exchange rates. The same range applies to adjusted operating profit growth. Both figures mark an improvement on the prior forecast of minus 6% to 0%, also at constant currencies.
Third-quarter 2026 adjusted revenue came in at DKK 79.2 billion, a gain of 4% at constant exchange rates. Adjusted operating profit climbed 27% over the same period to DKK 31.7 billion, again on a constant-currency basis. Sales of the Wegovy tablet, meanwhile, reached DKK 5.39 billion.
La Corte to Take Over Finance Reins
Novo Nordisk also named Luigi La Corte as Executive Vice President and Chief Financial Officer on Wednesday, Reuters reported. La Corte joins from Galderma, where he held the same CFO role. He succeeds Karsten Munk Knudsen, who will leave the company at the end of the year to pursue other career opportunities.
Separately, Novo Nordisk presented findings from its PLATINUM-Truveta and RHODIUM-2 care studies on Friday. The research linked the use of Wegovy in adults with MASH to reductions in liver enzymes, body weight and blood sugar. The results were unveiled at the AASLD liver congress.
Ad
Novo Nordisk Stock: New Analysis - 9 November
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
